Stallergenes reports good sales growth

French biopharmaceutical company Stallergenes' total sales for the first half of 2008 were up 16% on the same period of the year before, amounting to 87.0 million euros ($136.3 million).

The firm's largest market during this period was southern Europe, bringing 75% of total sales. Revenue there was 64.7 million euros, up 14% on the year before. The rest of the European Union accounted for 21% of sales, 18.6 million euros, which was up 18%. Other markets accounted for 4% of sales, 3.7 million euros, up 46% on the year-before period.

In the second quarter of the year alone, the firm generated in turnover of 38.0 million euros, up 18% on the year before. 71% of total sales came from southern Europe, 26.8 million euros, a 15% rise. Other countries in the EU accounted for 24% of sales, up 20% to 9.3 million euros. The remaining 5% of sales amounted to 2.0 million euros, up 47% on the same period in 2007.